<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="brief-report" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CPJ</journal-id>
<journal-id journal-id-type="hwp">spcpj</journal-id>
<journal-id journal-id-type="nlm-ta">Clin Pediatr (Phila)</journal-id>
<journal-title>Clinical Pediatrics</journal-title>
<issn pub-type="ppub">0009-9228</issn>
<issn pub-type="epub">1938-2707</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0009922811412942</article-id>
<article-id pub-id-type="publisher-id">10.1177_0009922811412942</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Brief Reports</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Atypical Hemolytic–Uremic Syndrome in a Child Presenting With Malignant Hypertension</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Totina</surname><given-names>Alisha</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0009922811412942">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Iorember</surname><given-names>Franca</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0009922811412942">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>El-Dahr</surname><given-names>Samir S.</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0009922811412942">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Yosypiv</surname><given-names>Ihor V.</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0009922811412942">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-0009922811412942"><label>1</label>Tulane University Health Sciences Center, New Orleans, LA, USA</aff>
<author-notes>
<corresp id="corresp1-0009922811412942">Ihor V. Yosypiv, Department of Pediatrics, SL-37, Tulane University Health Sciences Center, 1430 Tulane Avenue, New Orleans, LA 70112, USA Email: <email>iiosipi@tulane.edu</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>2</month>
<year>2013</year>
</pub-date>
<volume>52</volume>
<issue>2</issue>
<fpage>183</fpage>
<lpage>186</lpage>
<permissions>
<copyright-statement>© The Author(s) 2011</copyright-statement>
<copyright-year>2011</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
</article-meta>
</front>
<body>
<sec id="section1-0009922811412942" sec-type="intro">
<title>Introduction</title>
<p>Hemolytic–uremic syndrome (HUS) is a rare systemic disease characterized by the presence of microangiopathic hemolytic anemia, thrombocytopenia (platelet count &lt;150 × 10<sup>9</sup>/L) and kidney injury.<sup><xref ref-type="bibr" rid="bibr1-0009922811412942">1</xref></sup> Most children with HUS present with a watery or bloody diarrhea prodrome caused by Shiga toxin–producing enterohemorrhagic <italic>Escherichia coli</italic>.<sup><xref ref-type="bibr" rid="bibr2-0009922811412942">2</xref></sup> This form of disease is commonly referred to as diarrhea-positive HUS. Many patients require renal replacement therapy during the acute phase of disease, but kidney function recovers in most of them within several weeks.<sup><xref ref-type="bibr" rid="bibr1-0009922811412942">1</xref></sup> A minority of pediatric patients with HUS do not develop a diarrhea prodrome.<sup><xref ref-type="bibr" rid="bibr3-0009922811412942">3</xref></sup> This form of disease is commonly referred to as diarrhea-negative or atypical HUS. Infection by Shiga toxin–producing <italic>E coli</italic> is excluded as a cause in this form of disease. Importantly, the clinical outcome is unfavorable in atypical HUS. Up to 25% of patients die in acute phase of the disease and up to 50% of children progress to end-stage kidney disease (ESKD).<sup><xref ref-type="bibr" rid="bibr3-0009922811412942">3</xref>,<xref ref-type="bibr" rid="bibr4-0009922811412942">4</xref></sup></p>
<p>Atypical HUS may be sporadic or familial. It can be induced by infection (eg, <italic>Streptococcus pneumoniae</italic>), malignancy, ionizing radiation, cancer chemotherapy, organ transplantation, antibodies to complement-regulating factors, or genetic mutations.<sup><xref ref-type="bibr" rid="bibr5-0009922811412942">5</xref></sup> Familial atypical HUS is characterized by either autosomal dominant or recessive transmission.<sup><xref ref-type="bibr" rid="bibr6-0009922811412942">6</xref></sup> Recent genetic studies demonstrated that mutations in the genes encoding regulatory proteins of the complement cascade or a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13; von Willebrand factor protease) are associated with the development of atypical HUS.<sup><xref ref-type="bibr" rid="bibr7-0009922811412942">7</xref>,<xref ref-type="bibr" rid="bibr8-0009922811412942">8</xref></sup> Among complement regulatory proteins, mutations in the genes encoding complement factor H (CFH), membrane cofactor protein (MCP), and complement factor I (CFI) have been shown to be linked to atypical HUS.<sup><xref ref-type="bibr" rid="bibr7-0009922811412942">7</xref></sup> Mutations in these components cause hyperactivation of the complement cascade resulting in decreased levels of complement component C3 and are identified in 52% of children with atypical HUS.<sup><xref ref-type="bibr" rid="bibr8-0009922811412942">8</xref>,<xref ref-type="bibr" rid="bibr9-0009922811412942">9</xref></sup> Interestingly, clinical outcome differs depending on the type of mutated complement system component. The most severe prognosis is observed in the CFH mutation group 60% of whom reach ESKD or die within &lt;1 year. In contrast, MCP mutation–associated HUS has a relapsing course and none of the children reach ESKD at 1 year.<sup><xref ref-type="bibr" rid="bibr8-0009922811412942">8</xref></sup> Half of patients with CFI mutation have a rapid evolution to ESRD and half recover.</p>
<p>Plasma therapy (used to replace absent or mutated circulating complement components) combined with plasmapheresis (to remove mutant complement factors, anti-CFH antibodies, and other mediators of endothelial dysfunction, prevent volume expansion and hypertension) has a beneficial effect in one third of patients from all groups except for the MCP mutation group. Only 8 (33%) of 24 kidney transplantations that were performed in children with atypical HUS due to mutations in complement system components were successful.<sup><xref ref-type="bibr" rid="bibr8-0009922811412942">8</xref></sup> The risk of posttransplant recurrence is less than 1% in patients with Shiga toxin–induced HUS. In contrast, it is approximately 80% in atypical HUS due to CFH or CFI mutations, 20% in MCP mutations, and 30% in patients with no identifiable mutations.<sup><xref ref-type="bibr" rid="bibr7-0009922811412942">7</xref>,<xref ref-type="bibr" rid="bibr10-0009922811412942">10</xref></sup> Renal graft failure is due to early graft thrombosis (50%) or HUS recurrence (50%). This case highlights an unusual presentation of atypical HUS with malignant hypertension that preceded the onset of classical features of the disease.</p>
</sec>
<sec id="section2-0009922811412942" sec-type="cases">
<title>Case Report</title>
<p>A 10-month-old previously healthy African American female infant presented with acute onset of facial and lower extremity edema. There was no evidence of fever, vomiting, diarrhea, or change in urine output at initial presentation. The infant was born to nonconsanguineous parents and had an uncomplicated normal term delivery via a cesarean section. The patient had no significant past medical history. Family history revealed the loss of older male sibling at 4 months of age of an undetermined cause. At the time he presented with symptoms of lethargy. Within hours of presentations, he went into cardiac arrest and could not be successfully resuscitated.</p>
<p>Physical examination revealed an alert and active infant with peripheral, facial, and severe periorbital edema. Cardiac exam was unremarkable. The infant was warm, well perfused with good peripheral pulses and brisk capillary refill. Bilateral mild crackles were audible on her lung exam. Blood pressure was 200/120 mm Hg in all 4 extremities. Additional workup revealed severe hemolytic anemia with a hemoglobin of 6.0 g/dL, hematocrit of 16.0%, and platelet count of 271 000 per mm<sup>3</sup> (<xref ref-type="table" rid="table1-0009922811412942">Table 1</xref>). Peripheral blood smear revealed schistocytes. The infant was started on antihypertensive therapy with intravenous infusion of sodium nitroprusside followed by nicardipine, received packed red blood cell transfusions to correct anemia, and lasix in an attempt to minimize edema. Twelve-lead electrocardiogram showed left ventricle hypertrophy, which was confirmed by echocardiogram. Renal ultrasound demonstrated presence of 2 kidneys of normal for age size with poor corticomedullary differentiation, increased echogenicity bilaterally, and normal blood flow. Chemistry showed Na of 131, K of 4.4, chloride of 100, bicarbonate of 17, albumin of 1.9, blood urea nitrogen of 25, and creatinine of 0.7. Urinalysis demonstrated trace protein, +1 hemoglobin and 1 to 2 red blood cells. Hemoglobin electrophoresis studies revealed elevated hemoglobin F at 16%. ADAMTS13 activity, complement C3 and C4, ASO and DNase B, plasma aldosterone and renin, free T4, and thyroid-stimulating hormone levels were normal. Urine metanepherine, normetanephrine and vanillylmandelic acid (VMA), homovanillic acid (HVA) levels were normal. Magnetic resonance angiography ruled out renal artery stenosis or thrombosis. Results of a bone marrow biopsy and HIV serology were normal. Absence of hypokalemic metabolic alkalosis was not consistent with monogenic hypertension. The patient remained afebrile throughout her stay. Hospital course was characterized by progressive azotemia, oligoanuria and development of thrombocytopenia. Renal biopsy revealed presence of thrombotic microangiopathy (TMA) with a high degree of activity (<xref ref-type="fig" rid="fig1-0009922811412942">Figure 1</xref>). Immunofluorescent microscopy for IgA, IgG, IgM, C3, C1q, fibrinogen, and kappa and lambda light chains was negative. Electron microscopy showed glomerular capillary lumens obliterated by swollen endothelial cells, multifocal foot process effacement, and absence of dense deposits. A clinical diagnosis of atypical HUS was established and targeted investigations to determine genetic causes of HUS were commenced. Daily plasmapheresis with fresh frozen plasma infusions was promptly initiated. Progressive azotemia required later initiation of continuous veno-venous hemodiafiltration. Unfortunately, 3 weeks into the patient’s hospitalization she expired due to cardiac arrhythmia. Autopsy demonstrated presence of TMA in both kidneys, cecal and gastric petechiae, focal subpleural hemorrhages, cardiomegaly with left ventricle hypertrophy, and hepatosplenomegaly. Molecular analysis revealed absence of mutations in CFI, complement factor B (CFB), complement factor H-related 5 (CFHR5), MCP, complement C3, and presence of 158G→A transition in CFH of unknown significance.</p>
<table-wrap id="table1-0009922811412942" position="float">
<label>Table 1.</label>
<caption>
<p>Hematologic, Blood, and Urine Chemical Data</p>
</caption>
<graphic alternate-form-of="table1-0009922811412942" xlink:href="10.1177_0009922811412942-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Variable</th>
<th align="center">On Admission</th>
<th align="center">Hospital Day 8</th>
<th align="center">Hospital Day 15</th>
<th align="center">Hospital Day 21</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemoglobin (mg/dL)</td>
<td>6.0</td>
<td>7.6</td>
<td>9.2</td>
<td>8.1</td>
</tr>
<tr>
<td>Hematocrit (%)</td>
<td>16.0</td>
<td>21.1</td>
<td>27.0</td>
<td>24.0</td>
</tr>
<tr>
<td>Reticulocyte count (%)</td>
<td>5.6</td>
<td>2.5</td>
<td>3.1</td>
<td>2.5</td>
</tr>
<tr>
<td>Platelets (×10<sup>3</sup> per mm<sup>3</sup>)</td>
<td>271</td>
<td>348</td>
<td>100</td>
<td>20</td>
</tr>
<tr>
<td>Creatinine (mg/dL)</td>
<td>0.7</td>
<td>1.2</td>
<td>2.9</td>
<td>0.8</td>
</tr>
<tr>
<td>BUN (mg/dL)</td>
<td>25</td>
<td>31</td>
<td>63</td>
<td>6</td>
</tr>
<tr>
<td>Albumin (mg/dL)</td>
<td>1.9</td>
<td>2.3</td>
<td>2.5</td>
<td>2.7</td>
</tr>
<tr>
<td>Calcium (mg/dL)</td>
<td>8.4</td>
<td>8.5</td>
<td>7.4</td>
<td>7.0</td>
</tr>
<tr>
<td>Potassium (mg/dL)</td>
<td>4.4</td>
<td>4.2</td>
<td>3.7</td>
<td>5.3</td>
</tr>
<tr>
<td>Urine protein (mg/dL)</td>
<td>Trace</td>
<td>200</td>
<td>300</td>
<td>300</td>
</tr>
<tr>
<td>Urine hemoglobin</td>
<td>Moderate</td>
<td>Large</td>
<td>Large</td>
<td>Large</td>
</tr>
<tr>
<td>Urine red blood cells (cells/HPF)</td>
<td>1</td>
<td>25</td>
<td>664</td>
<td>550</td>
</tr>
<tr>
<td>Procedures</td>
<td>—</td>
<td>Renal biopsy</td>
<td>CVVHD</td>
<td>—</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0009922811412942">
<p>Abbreviations: BUN, blood urea nitrogen; HPF, high-power field; CVVHD, continuous veno-venous hemodiafiltration.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<fig id="fig1-0009922811412942" position="float">
<label>Figure 1.</label>
<caption>
<p>Microscopic examination of kidney biopsy specimen</p>
<p>A, B, Glomeruli (G) with increased cellularity, mesangiolysis, and fibrin thrombi. C, Fibrin deposition in arteriole (A). A and C—periodic acid-Schiff, B—Jones’s silver stain.</p>
</caption>
<graphic xlink:href="10.1177_0009922811412942-fig1.tif"/>
</fig>
</sec>
<sec id="section3-0009922811412942" sec-type="discussion">
<title>Discussion</title>
<p>The major causes of secondary hypertension in an infant include renal artery or vein thrombosis, renal artery stenosis, renal parenchymal diseases, congenital abnormalities of the kidney and urinary tract, coarctation of aorta, and endocrine and monogenic hypertension.<sup><xref ref-type="bibr" rid="bibr11-0009922811412942">11</xref>,<xref ref-type="bibr" rid="bibr12-0009922811412942">12</xref></sup> Absence of thrombocytopenia and renal injury at presentation did not prompt immediate consideration of atypical HUS. Therefore, initial diagnostic evaluation was focused on identifying causes of secondary hypertension. The negative workup for potential causes of secondary hypertension together with subsequent development of progressively worsening renal injury and thrombocytopenia indicated the possibility of atypical HUS and prompted initiation of targeted evaluation and therapy. No genetic mutations or other specific causes known to be associated with atypical HUS were identified.</p>
<p>Despite an improvement in our understanding of the etiology and pathophysiology of atypical HUS, the outcome remains poor. Efforts targeted at establishing a diagnostic and treatment consensus led to recent publication of guidelines for initial evaluation and management of atypical HUS in children.<sup><xref ref-type="bibr" rid="bibr5-0009922811412942">5</xref></sup> However, although plasma therapy and plasmapheresis are recommended in the treatment of atypical HUS in children, because of hereditary complement abnormalities, there is little consensus on the optimal long-term treatment regimen.<sup><xref ref-type="bibr" rid="bibr13-0009922811412942">13</xref></sup> Kidney transplantation can now be approached according to genotype with outcome more favorable in patients with MCP mutations.<sup><xref ref-type="bibr" rid="bibr7-0009922811412942">7</xref></sup> Given that CFH is synthesized in the liver, combined liver and kidney transplantation with pre-, intra-, and postoperative plasma therapy in patients with HUS due to MCP mutations has been proposed.<sup><xref ref-type="bibr" rid="bibr14-0009922811412942">14</xref></sup> Experimental therapies include utilization of eculizumab, a humanized monoclonal anti-complement factor C5 antibody.<sup><xref ref-type="bibr" rid="bibr15-0009922811412942">15</xref></sup></p>
<p>We propose that evidence of microangiopathy in a child with severe hypertension should prompt the clinician to investigate the possibility of atypical HUS.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict">
<label>Declaration of Conflicting Interests</label>
<p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>The authors received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0009922811412942">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ruggenenti</surname><given-names>P</given-names></name>
<name><surname>Noris</surname><given-names>M</given-names></name>
<name><surname>Remuzzi</surname><given-names>G</given-names></name>
</person-group>. <article-title>Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura</article-title>. <source>Kidney Int</source>. <year>2001</year>;<volume>60</volume>: <fpage>831</fpage>-<lpage>846</lpage>.</citation>
</ref>
<ref id="bibr2-0009922811412942">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Boyce</surname><given-names>TG</given-names></name>
<name><surname>Swerdlow</surname><given-names>DL</given-names></name>
<name><surname>Griffin</surname><given-names>PM</given-names></name>
</person-group>. <source>Escherichia coli</source> <article-title>O157:H7 and the hemolytic-uremic syndrome</article-title>. <source>N Engl J Med</source>. <year>1995</year>;<volume>333</volume>:<fpage>364</fpage>-<lpage>368</lpage>.</citation>
</ref>
<ref id="bibr3-0009922811412942">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Taylor</surname><given-names>CM</given-names></name>
<name><surname>Chua</surname><given-names>C</given-names></name>
<name><surname>Howie</surname><given-names>AJ</given-names></name>
<name><surname>Risdon</surname><given-names>RA</given-names></name>
</person-group>. <article-title>Clinico-pathological findings in diarrhoea-negative haemolytic uraemic syndrome</article-title>. <source>Pediatr Nephrol</source>. <year>2004</year>;<volume>19</volume>:<fpage>419</fpage>-<lpage>425</lpage>.</citation>
</ref>
<ref id="bibr4-0009922811412942">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fitzpatrick</surname><given-names>MM</given-names></name>
<name><surname>Walters</surname><given-names>MD</given-names></name>
<name><surname>Trompeter</surname><given-names>RS</given-names></name>
<name><surname>Dillon</surname><given-names>MJ</given-names></name>
<name><surname>Barratt</surname><given-names>TM</given-names></name>
</person-group>. <article-title>Atypical (non-diarrhea-associated) hemolytic-uremic syndrome in childhood</article-title>. <source>J Pediatr</source>. <year>1993</year>;<volume>122</volume>:<fpage>532</fpage>-<lpage>537</lpage>.</citation>
</ref>
<ref id="bibr5-0009922811412942">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ariceta</surname><given-names>G</given-names></name>
<name><surname>Besbas</surname><given-names>N</given-names></name>
<name><surname>Johnson</surname><given-names>S</given-names></name>
<etal/>
</person-group>; <collab>European Paediatric Study Group for HUS</collab>. <article-title>Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome</article-title>. <source>Pediatr Nephrol</source>. <year>2009</year>;<volume>24</volume>:<fpage>687</fpage>-<lpage>696</lpage>.</citation>
</ref>
<ref id="bibr6-0009922811412942">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Berns</surname><given-names>JS</given-names></name>
<name><surname>Kaplan</surname><given-names>BS</given-names></name>
<name><surname>Mackow</surname><given-names>RC</given-names></name>
<name><surname>Hefter</surname><given-names>LG</given-names></name>
</person-group>. <article-title>Inherited hemolytic uremic syndrome in adults</article-title>. <source>Am J Kidney Dis</source>. <year>1992</year>;<volume>19</volume>:<fpage>331</fpage>-<lpage>334</lpage>.</citation>
</ref>
<ref id="bibr7-0009922811412942">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Caprioli</surname><given-names>J</given-names></name>
<name><surname>Noris</surname><given-names>M</given-names></name>
<name><surname>Brioschi</surname><given-names>S</given-names></name>
<etal/>
</person-group>; <collab>International Registry of Recurrent and Familial HUS/TTP</collab>. <article-title>Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome</article-title>. <source>Blood</source>. <year>2006</year>;<volume>108</volume>:<fpage>1267</fpage>-<lpage>1279</lpage>.</citation>
</ref>
<ref id="bibr8-0009922811412942">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sellier-Leclerc</surname><given-names>AL</given-names></name>
<name><surname>Fremeaux-Bacchi</surname><given-names>V</given-names></name>
<name><surname>Dragon-Durey</surname><given-names>MA</given-names></name>
<etal/>
</person-group>; <collab>French Society of Pediatric Nephrology</collab>. <article-title>Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome</article-title>. <source>J Am Soc Nephrol</source>. <year>2007</year>;<volume>18</volume>:<fpage>2392</fpage>-<lpage>2400</lpage>.</citation>
</ref>
<ref id="bibr9-0009922811412942">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Noris</surname><given-names>M</given-names></name>
<name><surname>Ruggenenti</surname><given-names>P</given-names></name>
<name><surname>Perna</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: role of factor H abnormalities</article-title>. <source>J Am Soc Nephrol</source>. <year>1999</year>;<volume>10</volume>: <fpage>281</fpage>-<lpage>292</lpage>.</citation>
</ref>
<ref id="bibr10-0009922811412942">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Loirat</surname><given-names>C</given-names></name>
<name><surname>Fremeaux-Bacchi</surname><given-names>V</given-names></name>
</person-group>. <article-title>Hemolytic uremic syndrome recurrence after renal transplantation</article-title>. <source>Pediatr Transplant</source>. <year>2008</year>;<volume>12</volume>:<fpage>619</fpage>-<lpage>629</lpage>.</citation>
</ref>
<ref id="bibr11-0009922811412942">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brady</surname><given-names>TM</given-names></name>
<name><surname>Feld</surname><given-names>LG</given-names></name>
</person-group>. <article-title>Pediatric approach to hypertension</article-title>. <source>Semin Nephrol</source>. <year>2009</year>;<volume>29</volume>:<fpage>379</fpage>-<lpage>388</lpage>.</citation>
</ref>
<ref id="bibr12-0009922811412942">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Garovic</surname><given-names>VD</given-names></name>
<name><surname>Hilliard</surname><given-names>AA</given-names></name>
<name><surname>Turner</surname><given-names>ST</given-names></name>
</person-group>. <article-title>Monogenic forms of low-renin hypertension</article-title>. <source>Nat Clin Pract Nephrol</source>. <year>2006</year>;<volume>2</volume>:<fpage>624</fpage>-<lpage>630</lpage>.</citation>
</ref>
<ref id="bibr13-0009922811412942">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lapeyraque</surname><given-names>AL</given-names></name>
<name><surname>Wagner</surname><given-names>E</given-names></name>
<name><surname>Phan</surname><given-names>V</given-names></name><etal/>
</person-group>. <article-title>Efficacy of plasma therapy in atypical hemolytic uremic syndrome with complement factor H mutations</article-title>. <source>Pediatr Nephrol</source>. <year>2008</year>;<volume>23</volume>:<fpage>1363</fpage>-<lpage>1366</lpage>.</citation>
</ref>
<ref id="bibr14-0009922811412942">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Saland</surname><given-names>JM</given-names></name>
<name><surname>Ruggenenti</surname><given-names>P</given-names></name>
<name><surname>Remuzzi</surname><given-names>G</given-names></name>
</person-group>. <article-title>Liver-kidney transplantation to cure atypical hemolytic uremic syndrome</article-title>. <source>J Am Soc Nephrol</source>. <year>2009</year>;<volume>20</volume>:<fpage>940</fpage>-<lpage>949</lpage>.</citation>
</ref>
<ref id="bibr15-0009922811412942">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nürnberger</surname><given-names>J</given-names></name>
<name><surname>Philipp</surname><given-names>T</given-names></name>
<name><surname>Witzke</surname><given-names>O</given-names></name>
<etal/>
</person-group>. <article-title>Eculizumab for atypical hemolytic-uremic syndrome</article-title>. <source>N Engl J Med</source>. <year>2009</year>;<volume>360</volume>:<fpage>542</fpage>-<lpage>544</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>